A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® Gel 3% in the Treatment of Actinic Keratosis
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare the relative efficacy and safety of the test
formulation diclofenac sodium gel 3% (Taro Pharmaceuticals Inc.) to the marketed formulation
Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms) in the treatment of actinic keratosis.
Both the test and reference formulations will also be compared to a placebo formulation to
test for superiority.